Zhongzhi Pharmaceutical Holdings Limited (3737.HK)
HKD 0.89
(-2.2%)
HKD 0.89
(-2.2%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.01 Billion CNY | 9.11% |
| 2022 | 934.13 Million CNY | -6.27% |
| 2021 | 996.67 Million CNY | 20.27% |
| 2020 | 828.72 Million CNY | 21.41% |
| 2019 | 682.56 Million CNY | 11.66% |
| 2018 | 611.29 Million CNY | 28.12% |
| 2017 | 477.13 Million CNY | 40.76% |
| 2016 | 338.97 Million CNY | 23.21% |
| 2015 | 275.11 Million CNY | 33.97% |
| 2014 | 205.36 Million CNY | 7.04% |
| 2013 | 191.85 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 524 Million CNY | -0.3% |
| 2023 Q2 | 507.13 Million CNY | -3.48% |
| 2023 FY | 1.01 Billion CNY | 9.11% |
| 2023 Q4 | 525.56 Million CNY | 3.63% |
| 2022 FY | 934.13 Million CNY | -6.27% |
| 2022 Q2 | 408.74 Million CNY | -23.13% |
| 2022 Q4 | 525.39 Million CNY | 28.54% |
| 2021 FY | 996.67 Million CNY | 20.27% |
| 2021 Q2 | 464.91 Million CNY | 0.79% |
| 2021 Q4 | 531.75 Million CNY | 14.38% |
| 2020 Q2 | 367.46 Million CNY | -0.84% |
| 2020 FY | 828.72 Million CNY | 21.41% |
| 2020 Q4 | 461.26 Million CNY | 25.52% |
| 2019 FY | 682.56 Million CNY | 11.66% |
| 2019 Q4 | 370.58 Million CNY | 18.78% |
| 2019 Q2 | 311.98 Million CNY | -3.98% |
| 2018 Q2 | 286.36 Million CNY | 5.04% |
| 2018 FY | 611.29 Million CNY | 28.12% |
| 2018 Q4 | 324.92 Million CNY | 13.47% |
| 2017 Q2 | 204.51 Million CNY | 13.69% |
| 2017 Q4 | 272.62 Million CNY | 33.3% |
| 2017 FY | 477.13 Million CNY | 40.76% |
| 2016 Q4 | 179.88 Million CNY | 13.07% |
| 2016 FY | 338.97 Million CNY | 23.21% |
| 2016 Q2 | 159.09 Million CNY | -2.73% |
| 2015 Q4 | 163.56 Million CNY | 46.62% |
| 2015 Q2 | 111.55 Million CNY | -0.76% |
| 2015 FY | 275.11 Million CNY | 33.97% |
| 2014 FY | 205.36 Million CNY | 7.04% |
| 2014 Q2 | 92.95 Million CNY | 51046.08% |
| 2014 Q4 | 112.4 Million CNY | 20.92% |
| 2013 FY | 191.85 Million CNY | 0.0% |
| 2013 Q4 | 181.75 Thousand CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 24.42 Million HKD | -4073.19% |
| Grand Pharmaceutical Group Limited | 3.86 Billion HKD | 73.599% |
| Extrawell Pharmaceutical Holdings Limited | 35.52 Million HKD | -2768.973% |
| Wai Yuen Tong Medicine Holdings Limited | 353.93 Million HKD | -187.981% |
| Qianhai Health Holdings Limited | 17.1 Million HKD | -5859.888% |
| Lee's Pharmaceutical Holdings Limited | 590.99 Million HKD | -72.466% |
| Essex Bio-Technology Limited | 1.22 Billion HKD | 17.063% |
| Tongfang Kontafarma Holdings Limited | 503.46 Million HKD | -102.45% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -370.509% |
| SSY Group Limited | 1.98 Billion HKD | 48.541% |
| JBM (Healthcare) Limited | 163.87 Million HKD | -521.97% |
| Jacobson Pharma Corporation Limited | 287.34 Million HKD | -254.712% |
| China Resources Pharmaceutical Group Limited | 29.35 Billion HKD | 96.528% |